Abstract Chromosomal region 13q21-q22 harbors a putative breast cancer susceptibility gene and has been implicated as a common site for somatic deletions in a variety of malignant tumors. We have built a complete physical clone contig for a region between D13S1308 and AFM220YE9 based on 18 yeast artificial chromosome and 81 bacterial artificial chromosome (BAC) clones linked together by 22 genetic markers and 61 other sequence tagged sites. Combining data from 47 sequenced BACs (as of June 2001), we have assembled in silico an integrated 5.7-Mb genomic map with 90% sequence coverage. This area contains eight known genes, two hypothetical proteins, 24 additional Unigene clusters, and approximately 100 predicted genes and exons. We have determined the cDNA and genomic sequence, and tissue expression profiles for the KIAA1008 protein (homologous to the yeast mitotic control protein dis3+), KLF12 (AP-2 repressor), progesterone induced blocking factor 1, zinc finger transcription factor KLF5, and LIM domain only-7, and for the hypothetical proteins FLJ22624 and FLJ21869. Mutation screening of the five known genes in 19 breast cancer families has revealed numerous polymorphisms, but no deleterious mutations. These data provide a basis and resources for further analyses of this chromosomal region in the development of cancer.
Introduction
We recently reported on a putative breast cancer candidate predisposition locus at 13q21-q22 based on linkage analysis of 77 Finnish, Icelandic, and Swedish families that were negative for mutations in the BRCA1 and BRCA2 genes (Kainu et al. 2000) . A multipoint heterogeneity LOD score of 3.46 was obtained for the interval between the genetic markers D13S1296 and D13S1308. Comparative genomic hybridization and loss of heterozygosity (LOH) studies have suggested that 13q21 is also a common region of somatic loss in sporadic breast cancer (Larramendy et al. 2000; Wistuba et al. 1998) , malignant fibrous histiocytoma (Larramendy et al. 1997; Mairal et al. 1999) , and prostate cancer (Dong et al. 2000) . In prostate cancer, the minimal deletion area spans up to 3 Mb between markers D13S275 and D13S162 partly overlapping with the site implicated in breast cancer predisposition.
Because of several clues suggesting involvement of the 13q21-q22 area in cancer predisposition and progression, we undertook physical and transcript mapping of this locus, by using a combination of traditional positional cloning methods and new approaches based on the human genome draft sequence. The goal was to generate resour-ces for cloning potential cancer-associated genes, focusing particularly at a region between markers D13S1302 and D13S162. The genes in the region were identified by analysis of genomic sequence and cDNA cloning. The exon-intron structure and expression pattern was determined for seven of the genes in the region: genes for KIAA1008 (homologous to the yeast mitotic control protein DIS3), PIBF1 (progesterone induced blocking factor 1), KFL5 (Kruppel-like factor 5, also known as IKLF), KLF12 (Kruppel-like factor 12, also known as AP-2 repressor), LMO7 (LIM domain only-7), hypothetical protein FLJ21869, and hypothetical protein FLJ22624. Mutation screening of the five known genes was performed in 19 breast cancer families showing linkage to 13q21-q22 in order to investigate whether the genes are involved in breast cancer predisposition.
Materials and methods
Yeast artificial chromosome and bacterial artificial chromosome map Eighteen mega yeast artificial chromosomes (YACs) were selected from the Centre d'Étude du Polymorphisme Humain (CEPH) human YAC library by using genetic markers present in the interval between markers D13S1308 and D13S162 (Whitehead Institute for Biomedical Research/MIT Center for Genome Research, Human Physical Mapping Project: http://www-genome.wi.mit.edu/). Genome Systems (St. Louis, Mo.) human bacterial artificial chromosome (BAC) library releases I and II were screened by polymerase chain reaction (PCR), first with the existing genetic markers and then with newly defined sequence tagged sites (STSs). BAC DNA was isolated following the Qiagen (Santa Clara, Calif.) Plasmid Midi Kit (catalog no. 12143 or 12145). BAC insert ends were sequenced as described previously (Carpten et al. 2000) to generate additional STSs and to identify flanking clones by further PCR screening.
PCR for STS mapping PCR was carried out in 25-µl volumes in 96-well plates, in 1× PCR buffer II (Perkin Elmer), 2.25 mM MgCl 2 (Perkin Elmer), 0.2 mM dNTPs (Gibco-BRL), 0.8 µM of each of the primers, and 0.114 U/ µl AmpliTaq Gold Polymerase (Perkin Elmer) with 60 ng template in 2 µl. The following PCR program was used: one initial denaturation step at 94°C for 10 min, 34 cycles of 94°C for 30 s, 50°C or 55°C for 30 s, and 72°C for 1 min, followed by a final extension at 72°C for 10 min. PCRs were performed in an MJ Research thermocycler, PTC-225, and the products were checked in a 2% agarose gel.
Visual mapping by fluorescence in situ hybridization
Metaphase fluorescence in situ hybridization (FISH) was performed for low-resolution physical mapping and to identify chimeric clones. Metaphases were prepared from stimulated peripheral blood lymphocytes by standard techniques (Lundsteen and Lind 1985) . For high-resolution mapping, DNA fibers were obtained by incubation of the Epstein-Barr virus-immortalized lymphoblastoid cells in lysis buffer (2 M MgCl 2 , 25 mM TRIS-HCl, 1% Triton X) for 30 min at room temperature. Microscope slides were dipped into the lysis buffer, then taken out vertically, air dried for 5 min, and fixed in methanol:acetic acid (3:1) for 20 min. FISH was performed with DNA labeled with spectrum orange, spectrum green (Vysis, Downers Grove, Ill.) and Cy5 (Life Science Boston, Mass.) by nick translation, essentially as described by Pinkel et al. (1986) and Lichter et al. (1988) .
Transcript identification
All the expressed sequence tags (ESTs) and genes of the area between the genetic markers D13S1260 and D13S160 were screened by PCR against all possible YACs and BACs (GeneMap '98, http:// www.ncbi.nlm.nih.gov/genemap98; GeneMap'99, http://www.ncbi. nlm.nih.gov/genemap99). Additional genes in the area were identified from the analysis of the genomic sequence data that became available later (see below).
Transcript extension cDNA clones representing the genes of interest were obtained from Research Genetics (Huntsville, Ala.) and ATCC (Rockville, Md.) and further extended by the Rapid Amplification of cDNA Ends (Marathon RACE; Clontech, Palo Alto, Calif., catalog no. K1802-1) and by various methods of cDNA library screening (Rapid Screen cDNA libraries, Origene, Rockville, Md.; HUCL, Stratagene, La Jolla, Calif., catalog no. 937811; GeneTrapper cDNA Positive Selection System, Life Technologies, Rockville, Md., catalog no. 10356-020). Probes were designed from these sequences for Northern hybridizations in order to determine gene expression and the size of the transcripts.
Northern hybridization
Northern hybridizations were performed on multitissue blots supplied by Clontech (catalog nos. 7760-1, 7759-1, and 7767-1) with Hybrisol I (Intergen, Purchase, N.Y., catalog no. 54040) at 42°C. Washes were performed according to Sambrook et al. (1989) with a final stringency of 0.1×SSC (1×SSC=150 mM NaCl, 15 mM sodium citrate, pH 7.0) at 63°C.
Analysis of genomic sequence
The availability of the genomic sequence increased continuously as the project advanced, necessitating frequent comparisons between publicly available genomic sequences in the GenBank (http:// www.ncbi.nlm.nih.gov:80/entrez/viewer.cgi) and at the Sanger Centre (http://www.sanger.ac.uk/) with cDNA sequences arising from our own cDNA cloning efforts and those from public EST efforts. We used the WebBLAST program for this purpose (http://www. ncbi.nlm.nih.gov/blast/blast.cgi; Ferlanti et al. 1999) . Repetitive and vector sequences were first removed, and the edited sequences were used to search the nr, dbEST, and swissprot databases of NCBI with WebBLAST. Matches to dbEST were used to search the UniGene database (http://www.ncbi.nlm.nih.gov/UniGene/).
In order to access all the available genomic sequence, all ESTand STS-based markers were periodically searched against the genomic sequence databases (http://www.ncbi.nlm.nih.gov/genome/ sts/). Any new sequences were then BLASTed against the sequence databases in order to retrieve more overlapping BACs. Sequencher program was utilized to assemble the genomic contigs that were then analyzed with the GeneMachine program (http:// genome.nhgri.nih.gov/genemachine/; Makalowska et al. 1999 ) to find putative expressed sequences. GeneMachine has a graphical output that places BLAST results from the nr and dbEST databases in their base-pair position, along the sequence that is submitted. In addition, it provides the base-pair positions of predicted exons and genes from the programs MZEF, Grail, Fgenes, and GenScan.
Mutation analysis
Conformation-sensitive gel electrophoresis (CSGE; Ganguly et al. 1993) , as modified by Couch et al. (1996) , and direct sequencing (Carpten et al. 2000) were performed from both genomic DNA and cDNA extracted from lymphoblastoid cell lines established from patients or from whole blood sampled from patients. The sensitivity of the CSGE method is almost 90% (Ganguly et al. 1993) . DNA isolation was performed by using phenol-chloroform-isoamyl alcohol (25:24:1; Sambrook et al. 1989) , and RNA isolation was carried out with a Qiagen Rneasy Max Kit (catalog no. 75162). cDNA and genomic DNA derived from lymphoblastoid cell lines and from whole blood from 19 breast cancer families from Finland, Sweden, and Iceland were analyzed for mutations at each institution. The number of affected individuals per family range between 3 and 11, and the number of affected individuals tested per family was between one and three.
Results
Physical map of the 13q21-q22 critical region A complete physical clone map was assembled for the 13q21-q22 region between markers D13S1308 and AFM220YE9 by using 18 CEPH human megaYACs from the WC13.3 contig (http://www-genome.wi.mit.edu/) and 35 BACs (Genome Systems). The map was confirmed by STS-PCR with 22 genetic markers, 12 EST-derived STSs, and 61 novel STS derived from BAC end sequencing. In addition, all clones were checked for location and chimerism by metaphase-FISH analysis and 25 BAC clones also by dual color fiber-FISH to ascertain clone order over short distances and to ensure closure of the contigs.
As genomic sequences became available, we identified 47 sequenced BACs from the GenBank and assembled them in silico into six genomic contigs and then integrated them into our existing physical clone map (Fig. 1 , Table 1 ). The map spans approximately 6 cM in the Genethon genetic map (http://www.cephb.fr/bio/ceph-genethon-map. html) corresponding to about 5.7 Mb genomic DNA. Each of the six genomic contigs is anchored to the physical map by a genetic marker or EST and positioned relative to each other such that the size of the gaps correspond to the estimated size of the BACs that bridge them. Because of the changing nature of the incomplete public genomic maps (NCBI MapViewer and Human Genome Project Working Draft at UCSC), the overall base-pair position of our map should be considered as provisional. Although we do not have 100% sequence coverage, the BAC contig is complete. The gaps between contigs 2 and 3, and between contigs 3 and 4 were bridged by our BACs. The other gaps in the genomic sequence were bridged by unfinished sequenced BACs from the Human Genome Project. Altogether, only an estimated 400 kb of the 5.7 Mb of sequence between markers D13S1308 and AFM220YE9 remains to be sequenced.
Transcript identification
Based on recombinants in some breast cancer families, we considered the region from D13S1302 to D13S162 (3.3 Mb) to be the most important. We identified four known genes within this region: the genes for KIAA1008 protein (KIAA1008), KLF12, PIBF1, and KLF5 (Fig. 1 , Table 2 ). In initial mapping data, LMO7 was located proximal to marker D13S162 but later was verified to be located distal to this marker. This 3. 
Transcript characterization
Of the multiple known genes and various Unigene clusters mentioned above, the transcripts given below were further studied. Table 2 contains a summary of these transcripts.
Transcript of KIAA1008
KIAA1008 has a 40% identity with Saccharomyces cerevisiae mitotic control protein dis3+, a component of the yeast exosome (Shiomi et al. 1998) . By Northern analysis, we found it to be expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes (Fig. 2) . We extended the mRNA sequence to 7.3 kb (GenBank AF330044) and determined its intronexon structure (Fig. 3) . The gene spans 26.5 kb of genomic sequence and is comprised of 21 exons. It encodes a protein of 958 amino acids. It is transcribed divergently from PIBF1 whose 5' end is separated from it by only 200 bp.
Transcript of PIBF1
By Northern analysis, we found PIBF1 to be expressed most prominently in the testis and in spleen, thymus, prostate, ovary, small intestine and colon (Fig. 2) . We extended the mRNA sequence to 3.2 kb (GenBank AF33046), from which we determined the intron-exon structure (Fig. 3) . The gene spans 234.4 kb of genomic sequence and is comprised of 18 exons. It encodes a protein of 758 amino acids.
Transcript of KLF5
KLF5 (IKLF, CKLF, BTEB2) is a transactivator that binds the GC-box and epidermal growth factor (EGF) response element. Our Northern analysis (Fig. 2) and mRNA exten- CAGGGAAAGCGAACTACAGAAATC  AAGCATAAGGGGGAGCTTGATG  158  32i18R  G67303  CTTGAAGGATAACACATGGGC  CCAGTCAACCATCTCAACACAAAC  138  33j8F  G67304  GGAAGAGAGGGCTAGAAAAACACAG  GTGAGAAAGAAGGTGGGGAAATG  158  33j8R  G67305  GCCGAAGATAGTGAGGGAATG  GCTGTTGTAAAGATGCCAACTG  191  122g11F  G67306  TTCATCACCTGGCTTCCAAGAC  CAAGGAGTGCGTACAGACAGAAGAG  132  122g11R  G67363  CGGTAATTTTCCTTTCTTGCCC  GAACCAGCTTTTGCTTTCCCC  370  116d19F  G67307  GGGAAAGTAAGTGGCCTGTTG  CTAGATATGCCCAGTTCTACAAATC  204  116d19R  G67308  TTTCACTTGCTTTGACATGGTTTC  TTTAGCCCACTGACTCTTTTTTGC  115  178e6R  G67364  CCTCACAGAAACCTTCTGGG  AACTAACCTTGCCATTTC  104  283a3F  G67309  GGGCATTTTTAAGACCTGGAGAAG  CAGAGAAAGACAGGCATTTCCTTG  149  283a3R  G67310  GGGAAGTGGCTGATAAATGC  CAGACCATGCTCCTGTGAAG  103  84b6F  G67311  CTATGTTGGTCAGGCTGGTCTTG  CCCAGTCCATTAGTTCTCTGCTTTG  160  84b6R  G67312  GAAACAGAGCTGAAACACTGGTCTC  GCTCATAAGCCCCAAACCAATAG  249  173d1F  G67313  CGCAGGCACTTAAACATGGTATC  TGAAGGGGAAGCTCACAGTATCAC  177  173d1R  G67314  AAACAGTTTGGCAGTTCTCAACAAG  TCCCACTCATCAGTTGCTGGAC  176  123m6F  G67315  GCCACCCTTGAGATGTTGGAAC  ACTCAGGAGAGCCCCAGAATTG  231  123m6R  G67316  GCCACCATCTCAAAAATTGTCCAC  ACACCTACGAGGTAGCAAGCAGTC  216  42o17F  G67317  ACCTTTCCTGGGGTCTGAAC  CAGTGGTTTTTTGAGTCTCTATTTG  215  42o17R  G67318  TGGAGTTTGAACTGATGCAGTCTG  TGAAAGTGGGCAACCAGTATTCTC  375  153g21F  G67321  CTATCTTACATTCACCCGCTTC  CTTGTTAAACTCCAGGCATACG  106  153g21R  G67322  TTCAGGTCAGGTGCAGCAGTTC  CGAGGCAACAAGCATTAGGAAAG  112  221o10F  G67323  GGAAGGAGAGCACTGAGCTAAGTG  TTCAGGGGCTTTGCACAATG  233  221o10R  G67324  CTTAGTTTCTGCAACTCGGAGGAC  TAAAGACAAGGCTGTGGGTTCAG  195  209i2F  G67325  AAACGTGCCCATTTAAGCTGG  GCTAGGACAGGTCCCAACTTTTG  137  209i2R  G67326  TTCCTGACACCCTGGCTTTTC  GAAGATTGACATCATTTGGCAATTC  118  209e7F  G67327  GGAAAAGGGATTTCAGTCCAGAAG  GCTTTGATACTGCCAGTGTGTCATC  309  209e7R  G67328  AGGGGGTAAGGATCTCCTGACTTG  CACTGGGATGACCTTTGATTCTTG  169  199l5F  G67365  CCCATTTAAGCTGGTGAAATATC  CCAGGTCCCAACTTTTGAAC  124  199l5R  G67329  TTAGGGGTAAGGATCTCCTGACTTG  TCCACTGGGATGACCTTTGATTC  172  37k21R  G67330  CTATGAAATGGAGGAGATGAAAAC  TCTCAAATGCTTAAAGGCTCTATC  140  198e9F  G67331  GTACATGCCTGTGGTCTCAG  GGAGACAGGGTCTCACTTTG  135  198e9R  G67332  GGAACACAGCTACATCTTGCTGC  CCAGAACCTGGGAAGTGACTAATG  174  117n6F  G67333  GCACCACCAGAACTGGCTAAAAC  CAGAGGGCATGTTATTAGGGATCTG  142  117n6R  G67334  TCCTAATGTTCTCTGTCACAAGAAG  TTCTACTGCTTTGGGATCTATATTG  107  274h9F  G67335  TGACAGGGAAAAATCTCCAAG  AAACATCCATCTCAAAATG  188  274h9R  G67336  CACAAGCCTCGATGAGCTATG  AAGGTGAAGTAAAAGGTTAAGGAAG  264  288k21F  G67337  GCACACTATGCCTCCGTGTTAATG  GCTTTGGGAAGCCACGTATTTG  128  288k21R  G67338  TGGTGTTCGCTGGAACCTTTG  ACTAATGGCAAATCTGGCATCG  273  13g14F  G67339  GGAAGTGGAAAACATGAGTAAGCAG  TCAGTTGACTAGCCTGGACACAAG  113  56d5F  G67340  CAAAGAATAAGCTGCTTCTGGAC  TCTTAGTTACTGGGTATGTCCTAGC  141  56d5R  G67341  TTGGTTTTGCTGGGTCATCTTC  CATTAGGGAGAGTGGGATAAGGTTG  126  126o3F  G67362  GCCGAGGTTCTTTTCCTTG  CCTCCAGGCACTTACAATCTAAG  115  126o3R  G67342  GTGACTTGCTGATCGTGCATTG  CATTTGCCAGCCCATCTGTTC  258  308d14F  G67343  ATGAGACGGGCTTCACTGCATC  TTGACAAACTTTCTGTGCTGGTTG  158  308d14R  G67344  GTAATGCCTTACGTTTTAGAAAGTG  TGGTGTCTATTTTGACTGAACATC  127  374l18F  G67345  GCTCTTTTCATGCAGCTCCTAAATC  CCCATGCTCCATGTTTGTTTCTC  221  374l18R  G67346  CATTTAGGTCGGTGCCTGACAC  GAGATGTCCTTCACTGAAACTGGAG  249  511g14F  G67347  TCCTAATCTGTAAAATGGGGCTTG  TGCGTTTGGTAAATACTGTCCTTTG  109  511g14R  G67348  CCTGCCTCTATTCTTGCATACCAC  GCCATGAAGCAATGAGAAGTCAC  130  257f24F  G67349  TCTCCAAAATGACATGCTGTTC  CAAGAAAATTACCATCCCAGTG  112  257f24R  G67350  GAAATCATGGCTAATGCTCTAATC  GAAAAGGTTAAACCAAAACTACAGC  107  314h5F  G67351  CAGAGCCCATTCGCTATTAAAC  ATAAAGATTGGAGATGGTTACCTG  141  314h5R  G67352  ACTCGGGCTCAAATCTTTTC  TGGGAAAGAGGAATCCACAG  101  565a23R  G67353  TGCATTCTCCTCCAGACTTTG  GGTTTAGAGCAAAAGGGTATGTAG  159  413n5F  G67354  TTGTCCAAGTACAGGTATAAGGAAG  GAATTTAGGCAATCAAGTTGAC  163  413n5R  G67355  AAGACCTTGAGTGAGATGTGGTAG  AGAAAAAGCACGCAGTC  172  343d16F  G67356  ATTTAGCACTTCCTGAATGATGA  CACTGGGTAAAATGAGCTGAAAG  81  427n14F  G67357  CAGTTAAGGGGTTCAGAATCTAAG  CGCCATATTGTGTGAATCAATC  206  427n14R  G67358  CCTCCTTCAAAAAAGAGCAATC  AATCCCTCACTTCCAGAGACTAC  183  214f7F  G67359  GATTTGGCATTTAGAACTAGCTTC  GCTCAATATAATGTCTGGCTCAG  101  214f7R G67360 AAAAACAAACATGCCTCCTTC GCTCACAACCAAGTCTCCAATC 112 sion confirmed the previously published expression pattern and gene structure (Shi et al. 1999 ).
Transcript of KLF12
KLF12 (AP-2 repressor) binds to AP-2 transcription factor, which in turn regulates the expression of c-erb-2 in human mammary carcinoma (Bosher et al. 1995) . By Northern analysis, we found it to be expressed most prominently in peripheral blood leukocytes and more weakly in spleen, thymus, and colon (Fig. 2) . We extended the mRNA sequence to 10.6 kb (GenBank AF330041). The gene spans 308.9 kb of genomic sequence and is composed of seven exons. It encodes a protein of 402 amino acids.
Transcript of LMO7
LMO7 contains a single cysteine-rich zinc-binding LIM domain involved in protein-protein interactions (Putilina et al. 1998) . By Northern analysis, we found it to be expressed most prominently in lung, skeletal muscle and kidney, and in thymus, prostate, testis, colon, spinal cord, adrenal gland, placenta, and liver (Fig. 2) . We extended the mRNA sequence to 7.2 kb (GenBank AF330045). The gene spans 238.2 kb of genomic sequence and is comprised of 27 exons. It encodes a protein of 1349 amino acids.
Transcript of hypothetical protein FLJ21869
Hs.28465 encodes a hypothetical protein, FLJ21869, with no homology to other known proteins. By Northern analysis, we found it to be expressed most prominently in brain, heart, and skeletal muscle, in kidney and placenta, and faintly in all tissues, as a 2.4-kb transcript (Fig. 2) . Our mRNA extension confirmed the sequence in the Unigene database. The gene spans 19.1 kb of genomic sequence and is comprised of three exons. It encodes a short predicted protein of 82 amino acids. It is transcribed divergently from Hs.166425 whose 5' end is separated from it by only 287 bp.
Transcript of hypothetical protein FLJ22624
Hs.166425 encodes a hypothetical protein, FLJ22624, with no homology to known proteins. By Northern analysis, we found it to be expressed in adrenal gland, heart, ovary, pancreas, and kidney as a 4.4-kb transcript and in bone and placenta as a ~0.8-kb transcript (Fig. 2) . Our mRNA extension confirmed the sequence in the Unigene database. The gene spans 19.2 kb of genomic sequence and is comprised of 11 exons. It encodes a predicted protein of 519 amino acids. 
Transcript of HBCL13.1
By Northern analysis, we found HBCL13.1 (Table 2) to be expressed in trachea as a 1.8-kb transcript (Fig. 2) We extended its mRNA sequence to 1.8 kb (GenBank AF330043) but failed to uncover a probable coding sequence.
Transcript of HBCL13.2
By Northern analysis, we found HBCL13.2 (Table 2) to be expressed most prominently in testis and weakly in peripheral blood leukocytes as a 4.4-kb transcript (Fig. 2) . We were only able to extend its mRNA sequence to 1.5 kb (GenBank AF330042) and failed to uncover a probable coding sequence. The extended sequences for each mRNA were validated by RT-PCR. 3' ESTs matching these sequences revealed multiple possible polyadenylation sites. A list of these putative polyA sites and other clusters of ESTs are given for each of the known genes that were examined by Northern hybridization (Table 3) .
Mutation analysis
Five of the genes, KIAA1008, KLF12, PIBF1, LMO7, and KLF5, and the available sequence from hypothetical protein FLJ22624 were screened for germline mutations in breast cancer families by using CSGE and direct sequencing. No frame shift or nonsense mutations were found. One of the variants is located in a splice acceptor site i.e. C34 (-3)T in the KLF12 gene (Table 4 ). This nucleotide change did not segregate with the disease in the families in which it was found. It was also present in healthy controls. Five missense mutations were found that were not shared by the other affected members of the respective families and were therefore considered as polymorphisms. Altogether 21 different polymorphisms were found in these five genes, most of which are novel and represent a resource for developing SNP markers for these genes (Table 4) .
Discussion
We describe here the construction of a genomic map and the characterization of candidate genes in a genomic interval implicated in breast cancer predisposition and cancer progression. First, we constructed a 5.7-Mb genomic The two maps validated one another and made it possible to achieve greater than 90% coverage of contiguous genomic sequence, the majority of which is finished. Second, analysis of the genomic sequence uncovered eight genes in the interval and two predicted proteins and identified an additional set of 24 Unigene clusters, some of which were localized to this region for the first time. Third, for the most interesting genes in the region, we determined their exon-intron structure and their expression profile in multiple tissues. Finally, we performed a mutation analysis of five genes of potential relevance to cancer (PIBF1, KIAA1008, KLF12, KLF5, and LMO7) in breast cancer families and identified novel SNPs for further genetic analyses of these genes and this genomic region. During the time that this work was performed, the availability of genome sequence for this region increased from virtually zero to the present 90%. Assembly of a clone contig map that had complete coverage enabled us to ascertain that only about 400 kb of the total of 5.7 Mb remained to be sequenced in five small gaps that were closed with the novel BAC clones identified here. Taken together, our results provide a substantially more coherent and complete view of the region of interest compared with the fragmented unfinished sequence data available in the genomic databases for this region as of April 2001. For example, in the April 1, 2001 freeze, the NCBI map (http:// www.ncbi.nlm.nih.gov/genome/guide/human/) placed the genomic sequence contig 1 (Fig. 1) , which is anchored by marker D13S1308, approximately 30 Mb distal to our region at 13q31. However, two unfinished sequenced BACs, RP11-26a1 and RP11-150l15 (Human Genome Project), linked the contig where D13S1308 is located, to the rest of our map. The order of the markers in the UCSC map (http//:genome.ucsc.edu/), as of the December 12, 2000 freeze is consistent with the order presented here. Another example is the location of the gene for Acid Phosphatase 5, tartrate resistant (ACP5), which is included in the UCSC map and in the published human genome maps for this region (International Human Genome Sequencing Consortium 2001; Venter et al. 2001) . In our BLAST analyses of the transcripts in this area, this gene showed 99% homology to a sequence in chromosome 19p13.3-p13.2 and no homology to any other chromosome. Therefore, this gene was most likely incorrectly assigned to chromosome 13.
The global analysis of the sequence data indicates that this region in chromosome 13 is a gene-poor area, as suggested by the lower GC content (36%) reported by the International Human Genome Sequencing Consortium (2001). Besides the eight known genes, two predicted proteins, and 24 Unigene/EST clusters, we have also identified more than 100 other putative transcripts in the area based on gene and exon prediction programs from GeneMachine (http://genome.nhgri.nih.gov/genemachine/; Makalowska et al. 1999) . It is likely that several of these candidate transcripts will be false positives. Moreover, even some of the correct predictions may correspond to different exons of the same gene. This is the case for several of the Unigenes mapped to this area. In cloning full-length (Table 2) . Another way in which extra clusters of ESTs may be generated is demonstrated by the cluster of 3'ESTs that terminate at base pair 1979 of KLF5 (AF132818). The finding that a corresponding 2.0-kb band has not been seen in Northern analysis can be explained by false priming from a polyA stretch internal to the 3' untranslated region during the generation of the cDNA libraries.
Of the multiple real and putative transcripts in the 13q21-q22 region, five genes have biological functions that are potentially relevant in cancer. PIBF1 is released by activated lymphocytes during pregnancy and inhibits natural killer activity and prostaglandin synthesis, thereby protecting against abortion in vivo (Szekeres- Bartho et al. 1985 Bartho et al. , 1989 Bartho et al. , 1999 . KIAA1008 (Nagase et al. 1999; Shiomi et al. 1998 ) is a gene homologous to the dis3+ gene, a component of the exosome in fission yeast. It encodes a mitotic-control protein with a PIN (PilT amino terminus) domain, which is a novel signaling domain superfamily conserved from yeast to mammals (Makarova et al. 1999 ). KIAA1008 has been found to be overexpressed in colorectal cancers and in lung metastases of murine colon-adenocarcinoma (Lim et al. 1997 ). KLF12 and KLF5 are members of the mammalian Kruppel-like transcription factor family (Turner and Crossley 1999) . KLF12 (also called Ap-2 rep) is a zinc finger protein that binds to the AP-2α gene promoter and represses its expression (Roth et al. 2000) . AP-2 is an inducer of Her-2 oncogene expression in a nontumorigenic immortalized mammary epithelial cell line (Bosher et al. 1995) . KLF5 may be an activator of EGF (Shi et al. 1999) . Finally, LMO7 is a member of a group of proteins that are believed to have a transcription regulatory function through protein-protein interactions and other roles (Putilina et al. 1998 ). The LIM motif in LMO7 is a cysteine-rich double zinc-finger domain present in human, mouse, rat and Caenorhabditis elegans proteins (Putilina et al. 1998) . No deleterious mutations in any of these genes have been found in the 13q21-q22-linked breast cancer families so far analyzed suggesting that these genes may not have major significance as predisposition genes. However, further work to evaluate the potential significance of the missense mutations/polymorphisms is warranted, as is the analysis of somatic mutations, particularly in prostate cancer that shares this region as a deletion site (Dong et al. 2000) .
In conclusion, we describe the transcript, physical, and genomic maps for a 5.7-Mb region between D13S1308 and AFM220YE9 implicated in cancer development and progression. This region harbors eight known genes, 24 additional Unigene clusters, and more than 100 predicted genes or exons. Five known genes were studied in detail at the transcriptional level and were screened for mutations in 19 breast cancer families. Although deleterious mutations were not found in these families, these five genes and all the other newly defined candidate transcripts in the interval provide a rich resource and starting material for the identification of potential cancer-associated genes from this chromosomal site.
